Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,402.82 -22.03 -0.13%
S&P 500 1,861.79 -0.52 -0.03%
NASDAQ 4,086.75 0.53 0.01%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Tokai Pharmaceuticals Announces Appointment of Jodie Morrison as Chief Executive Officer



  Tokai Pharmaceuticals Announces Appointment of Jodie Morrison as Chief
  Executive Officer

Business Wire

CAMBRIDGE, Mass. -- March 28, 2013

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing
new treatments for prostate cancer, today announced the appointment of Jodie
Morrison to the position of chief executive officer. Ms. Morrison’s
appointment follows the recent departure of former president and chief
executive officer Martin Williams, who has left the company to pursue other
opportunities.

“Tokai has made impressive progress under Jodie’s clinical and operational
leadership since 2006,” said Seth Harrison, M.D., chairman of the Tokai Board
of Directors and managing general partner, Apple Tree Partners. “This is a
very exciting time for Tokai as the company continues to advance its lead
prostate cancer drug galeterone in the ongoing ARMOR2 Phase 2 study. We
believe galeterone has the potential to be an important new treatment option
for patients with advanced prostate cancer, and we are confident in Jodie’s
ability to continue to execute Tokai’s goals and drive the late-stage clinical
development of this program.”

Ms. Morrison has held multiple positions of increasing responsibility during
her nearly seven years at Tokai, most recently serving as chief operating
officer and vice president, clinical affairs. She has more than 15 years of
development experience in oncology, urology, women’s health and other
therapeutic areas. Prior to joining Tokai, Ms. Morrison was director of
clinical operations and medical affairs at Dyax Corporation, and she
previously held clinical management positions at both Curis, Inc. and at
Diacrin, Inc.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on
developing new treatments for prostate cancer. The company’s lead drug
candidate, galeterone (TOK- 001), is the first investigational new drug that
can decrease overall androgen receptor levels in prostate tumors and in which
three distinct mechanisms of action are combined to disrupt androgen receptor
signaling in one oncotherapeutic. Galeterone is currently being evaluated in a
Phase 2 study, ARMOR2, in patients with castration-resistant prostate cancer
(CRPC). Based in Cambridge, Massachusetts, Tokai is backed by Apple Tree
Partners and Novartis Venture Fund. For more information on the company and
galeterone, please visit www.tokaipharma.com.

Contact:

Pure Communications, Inc.
Caton Morris, 910-232-7166
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement